In 2017, the China Food and Drug Administration (CFDA) continued to deepen the comprehensive reform of its regulatory system. At the same time, the CFDA became a regulatory member of ICH in June 2017 and has started to implement various ICH guidelines. In 2018, many regulations will be updated and new regulations will be issued. In this forum, members from various organizations in the CFDA will present the latest progress of the major initiatives and the future directions of the regulatory reform in China.
Learning Objective : Discuss and understand the latest CFDA’s initiatives in regulatory reform and their impacts on Chinese pharmaceutical regulation and enforcement; Recognize China’s evolving regulatory environment and future development.